Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have extensive-stage small cell lung cancer that has responded to previous chemotherapy.
Key facts
- Study ID
- NCT00053300
- Run by
- Case Comprehensive Cancer Center
- People needed
- 30
- Starts
- 2002-08-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2010-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.